Table 2.
Summary of first-line panitumumab trials
| Trial | KRAS status | Treatment regimen | PFS (months) | HR (P-value) | OS (months) | HR (P-value) | ORR |
|---|---|---|---|---|---|---|---|
| Phase III | |||||||
| PRIME25 (n=1,183) |
KRAS-WT | FOLFOX4 + Pan | 10 | 0.8 (0.01) | 23.8 | 0.83 (0.03) | 57% |
| FOLFOX4 | 8.6 | 19.4 | 48% | ||||
| KRAS-MT | FOLFOX4 + Pan | 7.4 | 1.27 (0.02) | 15.5 | 1.17 (0.014) | 40% | |
| FOLFOX4 | 9.2 | 19.2 | 41% | ||||
| Phase II | |||||||
| PEAK35 (n=285) |
KRAS-WT exon 2 | FOLFOX + Pan | 10.9 | 0.87 (0.35) | 34.2 | 0.62 (0.009) | 57.8% |
| FOLFOX + Bev | 10.1 | 24.3 | 53.5% | ||||
| Kohne et al50 (n=154) |
Unselected | FOLFIRI + Pan | 7.6 | NR | 49% | ||
| KRAS-WT | FOLFIRI + Pan | 8.9 | NR | 56% | |||
| KRAS-MT | FOLFIRI + Pan | 7.2 | NR | 38% | |||
| Berlin et al51 (n=43) |
Unselected | FOLFIRI + Pan | 10.9 | 22.5 | 42% | ||
| Unselected | IFL + Pan | 5.6 | 17 | 46% | |||
Abbreviations: PFS, progression-free survival; HR, hazard ratio; OS, overall survival; ORR, overall response rate; Pan, panitumumab; FOLFOX, folinic acid/infusional 5-fluorouracil/oxaliplatin; Bev, bevacizumab; FOLFIRI, folinic acid/infusional 5-fluorouracil/irinotecan; IRL, folinic acid/bolus 5-fluorouracil/irinotecan; n, number of patients; NR, not reported.